Literature DB >> 28349755

Radical prostatectomy for locally advanced and metastatic prostate cancer.

R Veeratterapillay1, S S Goonewardene2, J Barclay1, R Persad3, C Bach1.   

Abstract

The management of advanced prostate cancer remains challenging. Traditionally, radical prostatectomy was discouraged in patients with locally advanced or node positive disease owing to the increased complication rate and treatment related morbidity. However, technical advances and refinements in surgical techniques have enabled the outcomes for patients with high risk prostate cancer to be improved. More recently, the concept of cytoreductive prostatectomy has been described where surgery (often Combined with an extended lymph node dissection) is performed in the setting of metastatic disease. Indirect evidence suggests an advantage using the cytoreductive approach. Hypothetical explanations for this observed benefit include decreased tumour burden, immune modulation, improved response to secondary treatment and avoidance of secondary complications attributable to local tumour growth. Nevertheless, prospective trials are required to investigate this further.

Entities:  

Keywords:  Cytoreductive surgery; Radical prostatectomy; Survival

Mesh:

Year:  2017        PMID: 28349755      PMCID: PMC5449684          DOI: 10.1308/rcsann.2017.0031

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  26 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

Authors:  Chao-Yu Hsu; Steven Joniau; Raymond Oyen; Tania Roskams; Hein Van Poppel
Journal:  Eur Urol       Date:  2006-06-09       Impact factor: 20.096

3.  Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.

Authors:  Martin Spahn; Steven Joniau; Paolo Gontero; Steffen Fieuws; Giansilvio Marchioro; Bertrand Tombal; Burkhard Kneitz; Chao-Yu Hsu; Katie Van Der Eeckt; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Hein Van Poppel
Journal:  Eur Urol       Date:  2010-03-17       Impact factor: 20.096

4.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

5.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

6.  Locally advanced prostate cancer: a population-based study of treatment patterns.

Authors:  William T Lowrance; Elena B Elkin; David S Yee; Andrew Feifer; Behfar Ehdaie; Lindsay M Jacks; Coral L Atoria; Michael J Zelefsky; Howard I Scher; Peter T Scardino; James A Eastham
Journal:  BJU Int       Date:  2011-11-15       Impact factor: 5.588

7.  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Authors:  Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin
Journal:  Eur Urol       Date:  2012-08-10       Impact factor: 20.096

8.  Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

Review 9.  The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.

Authors:  Georgios Gakis; Stephen A Boorjian; Alberto Briganti; Steven Joniau; Guram Karazanashvili; R Jeffrey Karnes; Agostino Mattei; Shahrokh F Shariat; Arnulf Stenzl; Manfred Wirth; Christian G Stief
Journal:  Eur Urol       Date:  2013-05-22       Impact factor: 20.096

10.  Is it truly outrageous to consider radical prostatectomy for men with metastatic prostate cancer?

Authors:  Gagan Gautam
Journal:  Indian J Urol       Date:  2014-10
View more
  8 in total

1.  The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.

Authors:  Se Young Choi; Bumjin Lim; Byung Hoon Chi; Wonchul Lee; Jung Hoon Kim; Yoon Soo Kyung; Dalsan You; Choung-Soo Kim
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

Review 2.  The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis.

Authors:  Yi Wang; Zhiqiang Qin; Yamin Wang; Chen Chen; Yichun Wang; Xianghu Meng; Ninghong Song
Journal:  Biosci Rep       Date:  2018-01-17       Impact factor: 3.840

3.  Preoperative PROSTATE scoring system: a potential predictive tool for the risk of biochemical recurrence after radical prostatectomy.

Authors:  Zhe-Nan Zhang; Cheng Luo; Ben Xu; Hai-Feng Song; Bing-Lei Ma; Qian Zhang
Journal:  Cancer Manag Res       Date:  2018-10-16       Impact factor: 3.989

4.  Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.

Authors:  Matthew G Parry; Arunan Sujenthiran; Thomas E Cowling; Julie Nossiter; Paul Cathcart; Noel W Clarke; Heather Payne; Ajay Aggarwal; Jan van der Meulen
Journal:  Int J Cancer       Date:  2019-01-17       Impact factor: 7.396

Review 5.  Is Retzius-sparing robot-assisted radical prostatectomy associated with better functional and oncological outcomes? Literature review and meta-analysis.

Authors:  Najib Isse Dirie; Gaurab Pokhrel; Wei Guan; Mukhtar Adan Mumin; Jun Yang; Jackson Ferdinand Masau; Henglong Hu; Shaogang Wang
Journal:  Asian J Urol       Date:  2018-02-09

6.  A Surveillance, Epidemiology and End Results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma.

Authors:  Yuyou Deng; Ran Bi; Zhenhua Zhu; Shengxian Li; Bo Xu; Wakeel Ahmad Rather; Chunxi Wang
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

7.  Sustainable functional urethral reconstruction: Maximizing early continence recovery in robotic-assisted radical prostatectomy.

Authors:  Zepeng Jia; Yifan Chang; Yan Wang; Jing Li; Min Qu; Feng Zhu; Huan Chen; Bijun Lian; Meimian Hua; Yinghao Sun; Xu Gao
Journal:  Asian J Urol       Date:  2020-01-27

8.  Very high-risk prostate cancer: multimodality treatment will be the new frontier.

Authors:  Davide Campobasso; Giuseppe Prati; Antonio Frattini
Journal:  Cent European J Urol       Date:  2017-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.